HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May...
-
Upload
marilyn-newman -
Category
Documents
-
view
216 -
download
2
Transcript of HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May...
![Page 1: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/1.jpg)
HPV as Primary Screening for Cervical Cancer: Ready for
Prime Time?
ACOG Annual Clinical MeetingMay 4, 2015
![Page 2: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/2.jpg)
Educational Objectives
• Proposed use of new FDA approved primary HPV screening test
• Advantages of primary HPV screening• Disadvantages of primary HPV screening
![Page 3: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/3.jpg)
The Panel
• Kevin Ault, MD - University of Kansas• Lori Boardman, MD - University of Central
Florida• Francisco Garcia, MD, MPH – Director and
CMO, Pima County Health Department• Moderator – David Chelmow, MD - Virginia
Commonwealth University
![Page 4: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/4.jpg)
Disclosures
• Ault – Site PI for clinical trials sponsored by Merck, Hologic, Roche, and Gen Probe until 2014*
• Boardman – none• Garcia – Site PI for clinical trials by Merck,
Hologic, Roche, Innovio and Photocure 1999-2013*
• Chelmow – none
*All payments directly to University
![Page 5: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/5.jpg)
Current recommendations
• USPSTF – Cytology alone or co-testing
• ACS (ACOG) – Co-testing preferred– Cytology alone acceptable
• Primary HPV testing discussed at 2012 ACS consensus conference, but not included in recommendation
![Page 6: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/6.jpg)
![Page 7: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/7.jpg)
Labeling- Primary Screening
• Women 25 and older• Positive for HPV 16 or 18 - colposcopy• HPV positive but 16/18 negative - cytology• Negative tests “should be followed up in
accordance with the physician’s assessment of screening and medical history, other risk factors, and professional guidelines”
![Page 8: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/8.jpg)
Obstetrics and Gynecology February 2015. Joint publication in Gynecologic Oncology and Journal of Lower Genital Tract Disease pending
![Page 9: HPV as Primary Screening for Cervical Cancer: Ready for Prime Time? ACOG Annual Clinical Meeting May 4, 2015.](https://reader036.fdocuments.in/reader036/viewer/2022062422/56649f315503460f94c4c1bc/html5/thumbnails/9.jpg)
Interim Guidance
• “. . . can be considered as an alternative to current US cytology based cervical cancer ‐screening methods”
• Manage positive tests as per labelling• Rescreen after negative test “no sooner than
every 3 years”• Do not use prior to age 25